^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Grit Biotechnology | N=16 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    1d
    A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older (clinicaltrials.gov)
    P1/2, N=1162, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed
    Trial completion
    1d
    An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia (clinicaltrials.gov)
    P=N/A, N=250, Not yet recruiting, Sanofi
    New trial
    2d
    IMCODE-004: A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) (clinicaltrials.gov)
    P2, N=62, Recruiting, Hoffmann-La Roche | N=362 --> 62
    Enrollment change
    |
    Opdivo (nivolumab) • autogene cevumeran (RG6180)
    3d
    Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review. (PubMed, J Skin Cancer)
    Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 positive
    3d
    YKYY031，tumors: Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=76, Not yet recruiting, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    BRAF V600E • KRAS G12C • BRAF V600 • KRAS G12D • KRAS G13D • KRAS G12R • KRAS G12 • KRAS G12S • KRAS G13
    5d
    A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. (clinicaltrials.gov)
    P3, N=3230, Recruiting, Pfizer
    New P3 trial
    5d
    Safety and Immunogenicity of NVX-CoV2705 (clinicaltrials.gov)
    P3, N=676, Completed, Sanofi | Active, not recruiting --> Completed | Trial primary completion date: Apr 2026 --> Jan 2026
    Trial completion • Trial primary completion date
    5d
    A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine (clinicaltrials.gov)
    P3, N=9320, Completed, Novavax | Trial completion date: Sep 2026 --> Feb 2026 | Trial primary completion date: Jul 2026 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    6d
    TIL cell therapy in HIV positive patient with metastatic melanoma: case report. (PubMed, Front Oncol)
    After multidisciplinary review, he underwent TIL harvest followed by lymphodepleting chemotherapy, lifileucel infusion, and high-dose interleukin-2 (IL-2)...This case demonstrates that TIL therapy can be feasibly administered to a patient with well-controlled HIV, with manageable toxicity and early radiographic response. These findings underscore the need for prospective inclusion of people living with HIV in cellular therapy trials to better characterize safety, immune dynamics, and predictors of durable benefit.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    BRAF V600E • BRAF V600
    |
    Amtagvi (lifileucel)
    6d
    The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants. (PubMed, Cancer Biol Ther)
    This review explores the dysfunctional immunological state of TNBC and proposes a multi-modal strategy integrating cryoablation as a source of tumor-associated antigens (TAAs) and immunostimulatory agents to reprogram antitumor immunity. It specifically explores the strategy of combining ICI and immunostimulants with cryoablation as a source of TAAs.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    PD-L1 expression • HR positive
    6d
    PREPARE: Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure (clinicaltrials.gov)
    P3, N=0, Withdrawn, Universitätsklinikum Hamburg-Eppendorf | N=70 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal